{{Rsnum
|rsid=1901440
|Chromosome=2
|position=133680388
|Orientation=plus
|GMAF=0.3567
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 46.8 | 44.1 | 9.0
| HCB | 65.0 | 29.2 | 5.8
| JPT | 65.2 | 31.2 | 3.6
| YRI | 5.4 | 42.9 | 51.7
| ASW | 26.8 | 33.9 | 39.3
| CHB | 65.0 | 29.2 | 5.8
| CHD | 66.7 | 30.6 | 2.8
| GIH | 52.5 | 37.6 | 9.9
| LWK | 23.9 | 52.3 | 23.9
| MEX | 48.3 | 39.7 | 12.1
| MKK | 26.3 | 50.6 | 23.1
| TSI | 40.2 | 50.0 | 9.8
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22293537
|Trait=None
|Title=A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
|RiskAllele=C
|Pval=0.000003
|OR=34.0000
|ORtxt=None
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}